Grufity logoGrufity logo

Pfizer Inc Stock Research

PFE

40.27USD-0.12(-0.30%)Delayedas of 27 Mar 2023, 11:24 am

Market Summary

USD40.27-0.12
Delayedas of 27 Mar 2023, 11:24 am
-0.30%

PFE Alerts

PFE Stock Price

PFE RSI Chart

PFE Valuation

Market Cap

226.5B

Price/Earnings (Trailing)

7.22

Price/Sales (Trailing)

2.26

EV/EBITDA

6.25

Price/Free Cashflow

8.7

PFE Price/Sales (Trailing)

PFE Profitability

EBT Margin

34.61%

Return on Equity

32.79%

Return on Assets

15.92%

Free Cashflow Yield

11.49%

PFE Fundamentals

PFE Revenue

Revenue (TTM)

100.3B

Revenue Y/Y

1.9%

Revenue Q/Q

7.3%

PFE Earnings

Earnings (TTM)

31.4B

Earnings Y/Y

47.19%

Earnings Q/Q

-41.98%

Price Action

52 Week Range

39.2354.96
(Low)(High)

Last 7 days

0.1%

Last 30 days

-4.7%

Last 90 days

-22.1%

Trailing 12 Months

-21.3%

PFE Financial Health

Current Ratio

1.22

PFE Investor Care

Dividend Yield

3.99%

Dividend/Share (TTM)

1.61

Buy Backs (1Y)

0.04%

Diluted EPS (TTM)

5.47

Peers (Alternatives to Pfizer)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
401.1B
94.9B
-3.25% -11.17%
22.36
4.23
1.25% -14.07%
302.8B
28.5B
2.15% 17.94%
48.48
10.61
0.79% 11.88%
272.8B
59.3B
-3.99% 33.34%
17.88
4.63
21.72% 11.27%
226.5B
100.3B
-4.70% -21.30%
7.22
2.26
23.43% 42.74%
143.9B
46.2B
-5.09% -4.47%
22.74
3.12
-0.49% -9.54%
MID-CAP
4.6B
4.5B
-7.51% -10.48%
-32.41
1.02
7.56% -104.06%
3.1B
2.2M
88.62% 133.17%
-10.04
1.4K
-80.71% -4.88%
SMALL-CAP
1.9B
667.2M
-7.26% 10.85%
31.38
2.86
15.09% 13.64%
1.6B
602.5M
-7.75% -62.41%
-2.78
2.67
18.18% -18.59%
923.6M
478.9M
-20.50% -75.95%
-0.29
1.93
-31.50% -634.70%
785.3M
285.2M
-7.87% -42.24%
3.57
2.75
-27.21% -40.28%
738.3M
114.5M
-10.60% -51.38%
-4.38
6.45
27.90% 57.40%
534.2M
29.8M
-36.88% -54.59%
-6.15
17.95
340.05% 4.35%
379.8M
51.5M
-18.81% -6.64%
-5.35
7.38
18.32% -984.05%
94.1M
2.3B
-43.99% -88.43%
-0.03
0.04
-22.53% -376.66%

Financials for Pfizer

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue0.5%100,33099,879101,27692,43381,288
  S&GA Expenses4.1%13,67713,13612,64412,51912,703
EBITDA4.2%36,17134,70833,95634,344-
EBITDA Margin3.7%0.36*0.35*0.34*0.37*-
Earnings Before Taxes4.2%34,72933,32532,16727,66924,311
EBT Margin3.7%0.35*0.33*0.32*0.30*-
Interest Expenses4.3%1,4421,3831,4401,4751,467
Net Income5.4%31,37229,77129,30924,96621,979
Net Income Margin4.9%0.31*0.30*0.29*0.27*-
Free Cahsflow11.4%26,03123,36228,44331,783-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets1.0%197,000195,000195,290183,841181,000
  Current Assets-27.2%51,25970,40367,46654,42059,693
    Cash Equivalents-68.0%4161,2981,7802,4701,944
  Inventory-5.6%8,9819,51310,4549,9799,059
  Net PPE5.4%16,27415,44115,24415,10914,882
  Goodwill6346.0%51,37579749,89150,21149,208
Liabilities-1.1%101,288102,459107,821101,155104,013
  Current Liabilities-4.9%42,13844,31447,41039,26842,671
    LT Debt, Current-0.2%2,5602,5661,2762601,636
    LT Debt, Non Current0.8%32,88432,62934,29435,65636,000
Shareholder's Equity3.3%95,66192,63187,46982,68577,201
  Retained Earnings2.2%125,656122,967116,608111,193103,394
  Additional Paid-In Capital0.5%91,80291,35991,18390,84490,591
Accumulated Depreciation-0.3%14,93114,96915,35815,074-
Shares Outstanding0.3%5,6075,5935,617--
Minority Interest-1.2%256259261261262
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations10.0%29,26726,59931,45434,58332,580
  Share Based Compensation-13.1%8721,0041,1621,0961,182
Cashflow From Investing-13.1%-15,783-13,959-23,408-20,232-22,546
Cashflow From Financing-12.6%-14,834-13,170-8,510-13,587-9,816
  Buy Backs0%2,0002,0002,0002,0000.00

Risks for PFE

What is the probability of a big loss on PFE?

46.1%


Probability that Pfizer stock will be more than 20% underwater in next one year

6.5%


Probability that Pfizer stock will be more than 30% underwater in next one year.

0%


Probability that Pfizer stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PFE drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Pfizer was unfortunately bought at previous high price.

Drawdowns

Returns for PFE

Cumulative Returns on PFE

7.2%


10-Year Cumulative Returns

8.1%


7-Year Cumulative Returns

6.8%


5-Year Cumulative Returns

14.6%


3-Year Cumulative Returns

What are the long-term rolling returns for PFE?

FIve years rolling returns for Pfizer.

Annualized Returns

Which funds bought or sold PFE recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
added
2.73
2,991,590
17,741,600
0.50%
2023-03-13
Claro Advisors LLC
added
7.02
130,979
2,972,980
0.97%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
3,878
23,878
-%
2023-03-10
Financial Alternatives, Inc
new
-
383,941
383,941
0.38%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-10.00
11,741,400
229,834,000
0.25%
2023-03-10
MATHER GROUP, LLC.
added
5.48
507,782
2,670,780
0.05%
2023-03-08
SHEETS SMITH WEALTH MANAGEMENT
reduced
-0.01
393,224
2,696,220
0.42%
2023-03-08
Capital Asset Advisory Services LLC
added
11.08
665,852
2,723,850
0.22%
2023-03-07
Nordwand Advisors, LLC
new
-
5,119,080
5,119,080
0.64%
2023-03-06
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-0.68
1,043,020
7,441,020
2.83%

1–10 of 47

Latest Funds Activity

Are funds buying PFE calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own PFE
No. of Funds

Pfizer News

InvestorsObserver

Is Pfizer Inc. (PFE) Stock Worth a Buy Monday?.

InvestorsObserver,
91 minutes ago

Nasdaq

Nasdaq

Yahoo Finance

Bear of the Day: Pfizer Inc. (PFE).

Yahoo Finance,
6 hours ago

Nasdaq

The Motley Fool

The Motley Fool

The Motley Fool

Nasdaq

Seeking Alpha

Seeking Alpha

Schedule 13G FIlings of Pfizer

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
8.94%
501,636,220
SC 13G/A
Feb 07, 2023
state street corp
5.08%
284,943,697
SC 13G/A
Feb 03, 2023
blackrock inc.
7.9%
442,868,761
SC 13G/A
Feb 14, 2022
state street corp
5.09%
285,771,591
SC 13G/A
Feb 10, 2022
vanguard group inc
8.29%
465,274,925
SC 13G/A
Feb 01, 2022
blackrock inc.
7.3%
409,985,645
SC 13G/A
Feb 12, 2021
state street corp
5.03%
279,831,373
SC 13G
Feb 10, 2021
vanguard group inc
8.06%
447,958,747
SC 13G/A
Jan 29, 2021
blackrock inc.
7.1%
396,973,512
SC 13G/A
Feb 13, 2020
state street corp
5.28%
292,628,794
SC 13G

PFE Fair Value

Pfizer fair value in different scenarios

The table shows the Fair Value estimates for Pfizer for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

-

-

-

-

-

-

-

-

-

-
Current Inflation

51.05

26.77%

62.08

54.16%

122.82

204.99%

161.21

300.32%

292.19

625.58%
Very High Inflation

-

-

-

-

-

-

-

-

-

-

Historical Pfizer Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Pfizer

View All Filings
Date Filed Form Type Document
Mar 23, 2023
4/A
Insider Trading
Mar 23, 2023
SC 13G/A
Major Ownership Report
Mar 22, 2023
PX14A6G
PX14A6G
Mar 21, 2023
4
Insider Trading
Mar 21, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
ARS
ARS
Mar 17, 2023
4
Insider Trading
Mar 17, 2023
4
Insider Trading
Mar 16, 2023
DEF 14A
DEF 14A

Latest Insider Trading transactions for PFE

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-15
DAMICO JENNIFER B.
sold
-396,678
40.02
-9,912
svp & controller
2023-02-27
SAHNI PAYAL
sold (taxes)
-52,891
40.78
-1,297
executive vice president
2023-02-27
DAMICO JENNIFER B.
sold (taxes)
-58,193
40.78
-1,427
svp & controller
2023-02-27
McDermott Michael
sold (taxes)
-125,643
40.78
-3,081
executive vice president
2023-02-25
SAHNI PAYAL
acquired
204,202
22.89
8,921
executive vice president
2023-02-25
DAMICO JENNIFER B.
acquired
255,224
22.89
11,150
svp & controller
2023-02-25
SUSMAN SALLY
acquired
1,670,600
22.89
72,984
executive vice president
2023-02-25
BOURLA ALBERT
sold (taxes)
-1,812,740
41.75
-43,419
chairman & ceo
2023-02-25
McDermott Michael
sold (taxes)
-392,417
42.9153
-9,144
executive vice president
2023-02-25
LANKLER DOUGLAS M
sold (taxes)
-1,101,740
41.75
-26,389
executive vice president

1–10 of 50

Albert Bourla
65535
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

PFE Income Statement

2022-12-31
Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Revenues$ 100,330$ 81,288$ 41,651
Costs and expenses:   
Cost of sales[1]34,34430,8218,484
Selling, informational and administrative expenses[1]13,67712,70311,597
Research and development expenses[1]11,42810,3608,709
Acquired in-process research and development expenses[2]9533,469684
Amortization of intangible assets3,6093,7003,348
Restructuring charges and certain acquisition-related costs1,375802579
Other (income)/deductions––net217(4,878)1,213
Income from continuing operations before provision/(benefit) for taxes on income[3],[4],[5]34,72924,3117,036
Provision/(benefit) for taxes on income3,3281,852370
Income from continuing operations31,40122,4596,666
Discontinued operations––net of tax6(434)2,529
Net income before allocation to noncontrolling interests31,40722,0259,195
Less: Net income attributable to noncontrolling interests354536
Net income attributable to Pfizer Inc. common shareholders$ 31,372$ 21,979$ 9,159
Earnings per common share––basic:   
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)$ 5.59$ 4.00$ 1.19
Discontinued operations––net of tax (in dollars per share)0(0.08)0.46
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)5.593.921.65
Earnings per common share––diluted:   
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)5.473.931.18
Discontinued operations––net of tax (in dollars per share)0(0.08)0.45
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)$ 5.47$ 3.85$ 1.63
Weighted-average shares––basic5,6085,6015,555
Weighted-average shares––diluted5,7335,7085,632
[1]Exclusive of amortization of intangible assets.
[2]See Note 1L.
[3]Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $314 million in 2022, $166 million in 2021 and $278 million in 2020. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $231 million of costs in 2021 and $222 million of costs in 2020 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation. Amortization of intangible assets is not allocated to our operating segments for all periods presented.
[4]2021 v. 2020––The domestic income in 2021 versus domestic loss in 2020 was mainly related to Comirnaty income, lower asset impairment charges, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and higher net gains from equity securities, partially offset by higher R&D expenses. The increase in the international income was primarily related to Comirnaty income, net periodic benefit credits in 2021 versus net periodic benefit costs in 2020 and lower asset impairment charges.
[5]2022 v. 2021––The decrease in domestic income is primarily related to net losses on equity securities in 2022 versus net gains on equity securities in 2021, lower net periodic benefit credits and higher restructuring charges and certain acquisition-related costs, partially offset by Paxlovid income and lower acquired IPR&D expenses. The increase in the international income is primarily related to Paxlovid and Comirnaty income partially offset by lower net periodic benefit credits.

PFE Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Assets  
Cash and cash equivalents$ 416$ 1,944
Short-term investments22,31629,125
Trade accounts receivable, less allowance for doubtful accounts: 2022—$449; 2021—$49210,95211,479
Inventories[1]8,9819,059
Current tax assets3,5774,266
Other current assets5,0173,820
Total current assets51,25959,693
Equity-method investments11,03316,472
Long-term investments4,0365,054
Property, plant and equipment16,27414,882
Identifiable intangible assets[2]43,37025,146
Goodwill[3]51,37549,208
Noncurrent deferred tax assets and other noncurrent tax assets6,6933,341
Other noncurrent assets13,1637,679
Total assets197,205181,476
Liabilities and Equity  
Short-term borrowings, including current portion of long-term debt: 2022—$2,560; 2021—$1,6362,9452,241
Trade accounts payable6,8095,578
Dividends payable2,3032,249
Income taxes payable1,5871,266
Accrued compensation and related items3,4073,332
Deferred revenues2,5203,067
Other current liabilities22,56824,939
Total current liabilities42,13842,671
Long-term debt32,88436,195
Pension and postretirement benefit obligations2,2503,724
Noncurrent deferred tax liabilities1,023349
Other taxes payable9,81211,331
Other noncurrent liabilities13,1809,743
Total liabilities101,288104,013
Commitments and Contingencies
Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding at December 31, 2022 and December 31, 202100
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2022—9,519; 2021—9,471476473
Additional paid-in capital91,80290,591
Treasury stock, shares at cost: 2022—3,903; 2021—3,851(113,969)(111,361)
Retained earnings125,656103,394
Accumulated other comprehensive loss(8,304)(5,897)
Total Pfizer Inc. shareholders’ equity95,66177,201
Equity attributable to noncontrolling interests256262
Total equity95,91677,462
Total liabilities and equity$ 197,205$ 181,476
[1]The decrease from December 31, 2021 reflects lower levels of Comirnaty, partially offset by new products acquired through recent acquisitions and higher Paxlovid inventory levels.
[2]The increase is primarily due to acquisitions (see Note 2A), partially offset by amortization expense.
[3]As a result of the organizational changes to the commercial structure within the Biopharma operating segment effective in the third quarter of 2022 (see Note 1A), our goodwill was required to be reallocated amongst impacted reporting units. The allocation of goodwill is a complex process that requires, among other things, that we determine the fair value of each reporting unit under our old and new organizational structure and the portions being transferred. We completed this re-allocation during the fourth quarter 2022 and concluded that none of our goodwill was impaired. Our goodwill balance continues to be assigned within the Biopharma reportable segment.